Teva Pharmaceutical (TEVA) Receives FDA Approval for Generic Uniretic Tablets
More News related to TEVA
- Teva Announces Approval and Launch of Tri-Lo Sprintec Tablets
- Teva (TEVA) and Antares (AIS) Announce FDA Approval of Needle-Free Injector for Tev-Tropin(R)
- Teva and Antares Announce FDA Approval of Needle-Free Injector Product for Administration of Tev-Tropin(R) (Human Growth Hormone)
- Teva Pharmaceutical (TEVA) and Active Biotech Complete Enrollment in Second Oral Laquinimod Phase III MS Clinical Trial
- Teva Pharma (TEVA) and Active Biotech Complete Patient Enrollment for Second Pivotal Phase III Trial of Laquinimod
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Application (ANDA) for Moexipril HCl and Hydrochlorothiazide Tablets, 7.5 mg/12.5 mg, 15 mg/12.5 mg and 15 mg/25 mg. Shipment of these products will begin immediately.
Teva's Moexipril HCl and Hydrochlorothiazide Tablets are the first AB-rated generic equivalent of Schwarz Pharma's Uniretic® Tablets, a product indicated for the treatment of hypertension.
The brand product had annual sales of approximately $30 million in the U.S., based on IMS sales data.
Related Categories
FDAStocks Mentioned
-0.49Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
